Hypertension Trial, Recruiting NCT06881082 Sponsor: Tanta University Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT06881082
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged over 18 years
  • People who have been diagnosed with cirrhosis (scarring of the liver)
  • People who have had an endoscopy (a camera procedure to look inside the digestive tract) showing medium or large swollen veins in the food pipe (esophageal varices)

Who may not be able to join:

  • People who have previously had bleeding from swollen veins in the food pipe, or who have already received preventive treatment for those veins
  • People who have a blood clot in the portal vein (the main blood vessel supplying the liver), or who have previously had a procedure to redirect blood flow around the liver (such as a TIPS procedure)
  • People who are currently taking medications that affect blood pressure in the liver, such as beta blockers or nitrates
  • People with serious heart conditions, including recent heart attack, certain heart rhythm problems, heart failure, poor circulation in the limbs, or an abnormally slow heart rate
  • People with severe lung conditions such as COPD (chronic obstructive pulmonary disease) or asthma
  • People with diabetes that is not well controlled
  • People with reduced kidney function
  • People who have liver cancer (hepatocellular carcinoma)
  • People who have a known allergy to a medication called carvedilol
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Nabila A Elgazzar, MD, Tropical medicine and infectious diseases Department, Faculty of Medicine, Tanta University

Phone: +201004672358

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
1 December 2024
Est. completion
30 November 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Vriceal bleeding rate at 6 weeks follow up; Mortality rate at 6 weeks follow up; Banding side effects at 6 weeks follow up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov